{
  "docId": "019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "docSlug": "UazyKuUCi7yVVPL3wJds",
  "documentTitle": "See the pitch deck that Compass Pathways used to raise $80 million and fuel its rise into one of the world's biggest psychedelics companies",
  "authorId": "Pitchdecks",
  "authorName": "Compass Pathways",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.333,
  "pageNumber": 2,
  "pageCount": 28,
  "prevPage": 1,
  "nextPage": 3,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": "The slide uses a structured list format to summarize key business pillars.",
  "elementsJson": [
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5f69-752d-a9b8-7335d4e4bbbd/2",
  "deckHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd",
  "deckJsonHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd.json",
  "deckAnchorHref": "/decks/019dd923-5f69-752d-a9b8-7335d4e4bbbd#slide-2",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "list",
      "text": "OPPORTUNITY: We address society’s largest unmet medical need: depression. Annual cost of depression of £300bn in EU and US alone. Initial focus: treatment-resistant depression (TRD), representing 100m patients out of 320m globally.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "134c21e7-b50c-4117-8dda-e6729171e94e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.88,
        "x": 0.06,
        "y": 0.31
      },
      "kind": "list",
      "text": "A SOLUTION: We are developing psilocybin therapy as safe, superior TRD therapy. Psilocybin therapy likely more efficacious, shorter in time, and at more affordable cost than alternatives.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4cb51cc9-4b9d-44b7-b043-819f06712bba",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.06,
        "y": 0.64
      },
      "kind": "list",
      "text": "UNIT ECONOMICS: We will sell psilocybin therapy to healthcare delivery points, get reimbursed for outcomes. Initial business model allows >50% contribution margin for COMPASS & clinics partners.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4eb6a7b2-2afe-44a1-a214-1c6bdfef92fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.06,
        "y": 0.49
      },
      "kind": "list",
      "text": "REASON TO BELIEVE: We work closely with top scientists, regulators, and technology players. Actively engaged, highly respected advisors and partners from leading institutions.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82181165-1b28-4883-a54a-43dc37f1dc8b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.88,
        "x": 0.06,
        "y": 0.79
      },
      "kind": "list",
      "text": "FINANCING: We raised £25m Series A in September 2018 for milestones to H2 2020. Next 18 months: initial results of largest psilocybin clinical trial in history.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba661b39-4854-4a32-bcbc-3248ca746c3a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.35,
        "x": 0.06,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Source: Analysis Group; EMA; Eurostat; FDA; OECD; WHO",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9b2517b3-51bd-48c9-85b2-f1b5e83fd6be",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.28,
        "x": 0.06,
        "y": 0.05
      },
      "kind": "title",
      "text": "Executive Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6ee05454-5ee2-41e7-bf66-533c774b32fb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "264ab9a6-3240-49a8-b30a-c72ea792bbb5",
      "evidence": "title/headline: Executive Summary",
      "confidence": 0.9
    }
  ],
  "frameworks": [
    {
      "name": "executive-summary",
      "slug": null,
      "matchId": "f9fd54ef-f544-47d6-9ce7-098bf4d9cfd5",
      "evidence": "Structured summary of business pillars",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}